EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

XTL Biopharmaceuticals Ltd (XTLB) fair value: what the stock is really worth

We calculate from audited financials what XTL Biopharmaceuticals Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 25, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ADR · ISIN US98386D3070

XB XTL Biopharmaceuticals Ltd logo Thin data Jul 25, 2026

XTL Biopharmaceuticals Ltd

XTLB · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $1.54 · Overvalued (−28.7%)
!Quality 29/100
!Weak Growth (revenue 5y +45.6 %/yr)
!negative free cash flow
✓Ranks above peers (2/3)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch XTL Biopharmaceuticals Ltd ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$20.80 $2.06 Fair Value $1.54 Feb 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.

How to read this chart

60‑month range $2.06 – $20.80 · fair‑value band $1.15 – $2.30 · the $2.16 price screens above the $1.54 fair value. Dashed = 300-day average. As of Jul 25, 2026.

Follow XTL Biopharmaceuticals Ltd ADR in your weekly email

Every Wednesday you see whether XTL Biopharmaceuticals Ltd ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Show more

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Stock analysis

XTL Biopharmaceuticals Ltd ADR (XTLB) currently trades at $2.16, while our model-based Fair Value estimate is $1.54, 28.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: $1.15 (bear) to $2.30 (bull), the price of $2.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

XTL Biopharmaceuticals Ltd ADR reported revenue of $451K in FY2024 versus $28.0K in FY2020, a compound +100.3%/yr. Reported net income was −$1.0M in FY2024.

Key figures

Market cap $6.6M · P/S ratio 6.81 · EPS (TTM) $−3.60 · Return on equity −577% · Return on assets (EBIT) −21.6% · Operating margin −854% · Revenue (TTM) $968K · EPS growth (YoY) −76.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 74% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −29%, XTLB screens richer than that median.

Fair Value models

Bear $1.15 Fair Value $1.54 Bull $2.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.15 $1.54 $2.30 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.15 $1.54 $2.30 51

Open the full fair value analysis →

Notify me when XTLB reaches fair value

Put XTLB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 31 · Market factors (momentum, volatility) 20

Profitability 0
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 24
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 66
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 18
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.6%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,220.3% (2019) → −481.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

XTLB screens overvalued: fair value 29% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare XTL Biopharmaceuticals Ltd ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 1/2 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Above median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

XTL Biopharmaceuticals Ltd ADR · Fair Value
$1.54 −29%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "XTL Biopharmaceuticals Ltd ADR Fair Value". https://www.fairvalue-calculator.com/stock/XTLB

Frequently asked questions

Is XTL Biopharmaceuticals Ltd (XTLB) overvalued or undervalued?
As of Jul 25, 2026, our model estimates a fair value of $1.54 versus a price of $2.16, about −29% upside (overvalued).
What is the fair value of XTLB?
Our model-based fair value for XTL Biopharmaceuticals Ltd ADR is $1.54 (as of Jul 25, 2026), built from audited fundamentals. The current price: $2.16.
What is the quality score of XTLB?
XTL Biopharmaceuticals Ltd ADR has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for XTL Biopharmaceuticals Ltd (XTLB)?
Our model-based price target is the fair value of $1.54 (as of Jul 25, 2026) from 1 valuation models. Cautious scenario $1.15, optimistic scenario $2.30. It is a calculation from audited fundamentals, not an analyst target.
What is the XTL Biopharmaceuticals Ltd ADR stock forecast for 2026?
Our models put fair value at $1.54, about −29% upside versus a price of $2.16 (overvalued). Cautious scenario $1.15, optimistic scenario $2.30. The calculation is refreshed regularly with new filings.
What is the revenue of XTL Biopharmaceuticals Ltd (XTLB)?
XTL Biopharmaceuticals Ltd ADR reported trailing-twelve-month revenue of about $968K (latest available figure, as of Jul 25, 2026).
What is the intrinsic value of XTL Biopharmaceuticals Ltd (XTLB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For XTL Biopharmaceuticals Ltd ADR it is $1.54 per share (as of Jul 25, 2026), against a price of $2.16. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is XTL Biopharmaceuticals Ltd ADR stock overvalued or undervalued in 2026?
As of Jul 25, 2026, XTLB trades above its calculated fair value: price $2.16, fair value $1.54, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XTLB?
No. The price is what the market pays today ($2.16); the fair value is what the company's own numbers justify ($1.54). For XTL Biopharmaceuticals Ltd ADR the two are $0.6200 per share apart. That gap is exactly why we show both numbers side by side.
How much is XTL Biopharmaceuticals Ltd ADR worth?
The market values XTL Biopharmaceuticals Ltd ADR at about $6.6M (market capitalisation, as of Jul 25, 2026). Per share that is $2.16; our models calculate a fair value of $1.54 per share.
What do the bullish and bearish scenarios say about XTLB?
Our models span a range for XTL Biopharmaceuticals Ltd ADR: cautious scenario $1.15, base $1.54, optimistic $2.30 per share (as of Jul 25, 2026, price $2.16). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is XTLB from its 52-week high?
XTL Biopharmaceuticals Ltd ADR trades at $2.16, about 74% below its 52-week high of $8.20 and 5% above the low of $2.06 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.54 is for.
Which stocks are comparable to XTL Biopharmaceuticals Ltd ADR?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is XTL Biopharmaceuticals Ltd ADR stock attractive at the current price?
The data as of Jul 25, 2026: price $2.16, calculated fair value $1.54 (−29%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XTLB calculated?
We run XTL Biopharmaceuticals Ltd ADR through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.54, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. XTL Biopharmaceuticals Ltd ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of XTL Biopharmaceuticals Ltd (XTLB)?
The closing price on Oct 2, 2026 was $2.16. Our model-based fair value is $1.54, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with XTL Biopharmaceuticals Ltd ADR right now?
Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($1.15 to $2.30) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of XTL Biopharmaceuticals Ltd ADR

How large is the market capitalisation of XTL Biopharmaceuticals Ltd (XTLB)?
The market capitalisation of XTL Biopharmaceuticals Ltd ADR is $6.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of XTL Biopharmaceuticals Ltd (XTLB)?
The price-to-sales ratio of XTL Biopharmaceuticals Ltd ADR is 6.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of XTL Biopharmaceuticals Ltd (XTLB)?
Earnings per share at XTL Biopharmaceuticals Ltd ADR are $−3.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of XTL Biopharmaceuticals Ltd (XTLB)?
The return on equity (ROE) of XTL Biopharmaceuticals Ltd ADR is −577% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of XTL Biopharmaceuticals Ltd (XTLB)?
On an EBIT basis the return on assets of XTL Biopharmaceuticals Ltd ADR is −21.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of XTL Biopharmaceuticals Ltd (XTLB)?
The operating margin of XTL Biopharmaceuticals Ltd ADR is −854% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at XTL Biopharmaceuticals Ltd (XTLB)?
Earnings per share at XTL Biopharmaceuticals Ltd ADR are growing −76.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does XTL Biopharmaceuticals Ltd (XTLB) generate?
The free cash flow of XTL Biopharmaceuticals Ltd ADR is −$1.7M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does XTL Biopharmaceuticals Ltd (XTLB) hold?
XTL Biopharmaceuticals Ltd ADR holds more cash than debt, $233K net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch XTL Biopharmaceuticals Ltd ADR in the live analysis

One click puts XTL Biopharmaceuticals Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.